Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Feature|Articles|August 30, 2024
New Treatments Are Changing the Future of Alzheimer Disease
Despite questions and controversy around some clinical research, new understandings of the pathophysiology of the disease are pushing treatments forward.
Advertisement
Advertisement
Recent FDA approvals and new scientific understandings have given patients and practitioners renewed hope for the future of Alzheimer disease (AD), which has long presented a challenge. As new treatments finally reach the public, pharmacists will play a growing role in counseling and ensuring patient access.
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
Advertisement
Advertisement